Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INSMED IncINSM · Entity 3174 | Director · Chair and CEO | July 23, 2026 | July 24, 2026 |
| NewAmsterdam Pharma Co N.V.NAMS · Entity 1826 | Director | January 07, 2026 | January 10, 2026 |
| uniQure N.V.QURE · Entity 4162 | Director | January 27, 2017 | January 31, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INSMED Inc
Report date July 23, 2026 · Filed July 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 259,058 |
Ending reported balance
After 2026-07-23 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-07-23 · Exercise / conversion · Acquired 6,260 · Balance 265,318 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Row 2 · 2026-07-23 · Exercise / conversion · Acquired 4,440 · Balance 269,758 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Row 3 · 2026-07-23 · Sale · Disposed 4,828 · Balance 264,930 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2: This is the weighted average sales price representing 4,828 shares sold at prices ranging from $105.09 to $106.02 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Row 4 · 2026-07-23 · Sale · Disposed 5,872 · Balance 259,058 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3: This is the weighted average sales price representing 5,872 shares sold at prices ranging from $106.09 to $106.78 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.46 · Expires 2028-01-04 | Direct | 0 |
Reported balance
After 2026-07-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-07-23 · Exercise / conversion · Disposed 6,260 · Balance 0 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.16 · Expires 2027-05-17 | Direct | 0 |
Reported balance
After 2026-07-23 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-07-23 · Exercise / conversion · Disposed 4,440 · Balance 0 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 233,924 |
Reported balance
Holding disclosure · report date 2026-07-23 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 233,924 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2: This is the weighted average sales price representing 4,828 shares sold at prices ranging from $105.09 to $106.02 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
F3: This is the weighted average sales price representing 5,872 shares sold at prices ranging from $106.09 to $106.78 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
F4: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.
NewAmsterdam Pharma Co N.V.
Report date January 07, 2026 · Filed January 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 10,360 |
Reported balance
After 2026-01-07 transaction · row 1
1 source rowRow 1 · 2026-01-07 · Grant · Acquired 3,400 · Balance 10,360 F1: Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date. F2: Each RSU was granted on January 7, 2026 for no consideration. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.45 · Expires 2036-01-07 | Direct | 15,300 |
Reported balance
After 2026-01-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-07 · Grant · Acquired 15,300 · Balance 15,300 F3: All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.
F2: Each RSU was granted on January 7, 2026 for no consideration.
F3: All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.
uniQure N.V.
Report date January 27, 2017 · Filed January 31, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.37 · Expires 2027-01-27 | Direct | 11,000 |
Reported balance
After 2017-01-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-27 · Grant · Acquired 11,000 · Balance 11,000 F1: The Stock Option vests 100% on January 27, 2018. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 16,000 |
Reported balance
After 2017-01-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-01-27 · Grant · Acquired 11,000 · Balance 16,000 F2: The Restricted Stock Unit vests 100% on January 27, 2018. F3: Expiration date is not applicable as the vested Restricted Stock Units shall be settled on the first business day following the date that such Restricted Stock Units vests. |
Filing footnotes · ownership attribution and instrument terms
F1: The Stock Option vests 100% on January 27, 2018.
F2: The Restricted Stock Unit vests 100% on January 27, 2018.
F3: Expiration date is not applicable as the vested Restricted Stock Units shall be settled on the first business day following the date that such Restricted Stock Units vests.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 15, 2025 Filed Jan 16, 2025 21:37 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 6,830 | $0.00 Strike: $10.85 | $0.00 |
DisclosureSEC source: 0001628280-25-001732 · wk-form4_1737063445.xml · derivative · entry 11 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 218,630 Underlying: Common Stock · 6,830 shares Expires 2026-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F8 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| January 15, 2025 Filed Jan 16, 2025 21:37 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 18,750 | $0.00 Strike: $22.76 | $0.00 |
DisclosureSEC source: 0001628280-25-001732 · wk-form4_1737063445.xml · derivative · entry 10 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 18,750 shares Expires 2025-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F8 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| January 15, 2025 Filed Jan 16, 2025 21:37 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 631 | $71.01 | $44,807.31 |
DisclosureSEC source: 0001628280-25-001732 · wk-form4_1737063445.xml · nonDerivative · entry 8 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 233,924 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F7 · price: This is the weighted average sales price representing 631 shares sold at prices ranging from $70.92 to $71.23 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 15, 2025 Filed Jan 16, 2025 21:37 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 4,700 | $70.31 | $330,457.00 |
DisclosureSEC source: 0001628280-25-001732 · wk-form4_1737063445.xml · nonDerivative · entry 7 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 234,555 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6 · price: This is the weighted average sales price representing 4,700 shares sold at prices ranging from $69.91 to $70.90 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 15, 2025 Filed Jan 16, 2025 21:37 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 1,499 | $69.40 | $104,030.60 |
DisclosureSEC source: 0001628280-25-001732 · wk-form4_1737063445.xml · nonDerivative · entry 6 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 239,255 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · price: This is the weighted average sales price representing 1,499 shares sold at prices ranging from $68.87 to $69.87 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 15, 2025 Filed Jan 16, 2025 21:37 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 6,830 | $10.85 | $74,105.50 |
DisclosureSEC source: 0001628280-25-001732 · wk-form4_1737063445.xml · nonDerivative · entry 5 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 240,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 15, 2025 Filed Jan 16, 2025 21:37 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 2,473 | $71.05 | $175,706.65 |
DisclosureSEC source: 0001628280-25-001732 · wk-form4_1737063445.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 379,534 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 2,473 shares sold at prices ranging from $70.89 to $71.37 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 15, 2025 Filed Jan 16, 2025 21:37 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 22,696 | $70.32 | $1,595,982.72 |
DisclosureSEC source: 0001628280-25-001732 · wk-form4_1737063445.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 382,007 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 22,696 shares sold at prices ranging from $69.89 to $70.89 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 15, 2025 Filed Jan 16, 2025 21:37 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 6,636 | $69.39 | $460,472.04 |
DisclosureSEC source: 0001628280-25-001732 · wk-form4_1737063445.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 404,703 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 6,636 shares sold at prices ranging from $68.87 to $69.86 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 15, 2025 Filed Jan 16, 2025 21:37 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 18,750 | $22.76 | $426,750.00 |
DisclosureSEC source: 0001628280-25-001732 · wk-form4_1737063445.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 411,339 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 10, 2025 Filed Jan 10, 2025 23:44 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 2,978 | $63.36 | $188,686.08 |
DisclosureSEC source: 0001628280-25-001203 · wk-form4_1736552690.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 392,589 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units (RSUs) and to cover related broker fees. Read SEC document |
| January 08, 2025 Filed Jan 10, 2025 23:44 UTC | INSMED Inc INSM · Entity 3174 | GrantStock Option (right to buy) · Derivative | 109,490 | $0.00 Strike: $65.72 | $0.00 |
DisclosureSEC source: 0001628280-25-001203 · wk-form4_1736552690.xml · derivative · entry 7 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,490 Underlying: Common Stock · 109,490 shares Expires 2035-01-08 F5 · derivative.exercise_date: These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the Initial Vesting Date and an additional 12.5% vest every six months thereafter until fully vested. Read SEC document |
| January 08, 2025 Filed Jan 10, 2025 23:44 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 22,824 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-001203 · wk-form4_1736552690.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 395,567 F3 · shares: Represents RSUs, each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan, as amended. The RSUs vest as follows: 25% on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 25% on each anniversary of the Initial Vesting Date until fully vested. F4 · price: Each RSU was granted on January 8, 2025 for no consideration. Read SEC document |
| January 08, 2025 Filed Jan 10, 2025 23:44 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 3,999 | $65.96 | $263,774.04 |
DisclosureSEC source: 0001628280-25-001203 · wk-form4_1736552690.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 372,743 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units (RSUs) and to cover related broker fees. Read SEC document |
| January 07, 2025 Filed Jan 8, 2025 23:03 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | GrantOrdinary Shares | 6,960 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-003561 · ownership.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,960 F1 · shares: Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date. F2 · price: Each RSU was granted on January 7, 2025 for no consideration. Read SEC document |
| January 07, 2025 Filed Jan 10, 2025 23:44 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 8,218 | $66.02 | $542,552.36 |
DisclosureSEC source: 0001628280-25-001203 · wk-form4_1736552690.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 376,742 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units (RSUs) and to cover related broker fees. F2 · price: This is the weighted average sales price representing 8,218 shares sold at prices ranging from $66.00 to $66.05 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 23:03 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | GrantOption (right to buy) · Derivative | 32,500 | $0.00 Strike: $25.85 | $0.00 |
DisclosureSEC source: 0000950170-25-003561 · ownership.xml · derivative · entry 2 Lewis William · CIK 0001402051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,500 Underlying: Ordinary Shares · 32,500 shares Expires 2035-01-06 F3 · derivative.exercise_date: 1/3 of the shares underlying the option will vest on January 6, 2026, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for two years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 23:52 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 6,830 | $0.00 Strike: $10.85 | $0.00 |
DisclosureSEC source: 0001628280-25-000403 · wk-form4_1735948354.xml · derivative · entry 7 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 225,460 Underlying: Common Stock · 6,830 shares Expires 2026-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 23:52 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 18,750 | $0.00 Strike: $22.76 | $0.00 |
DisclosureSEC source: 0001628280-25-000403 · wk-form4_1735948354.xml · derivative · entry 6 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,750 Underlying: Common Stock · 18,750 shares Expires 2025-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 23:52 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 6,830 | $69.86 | $477,143.80 |
DisclosureSEC source: 0001628280-25-000403 · wk-form4_1735948354.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 233,924 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 6,830 shares sold at prices ranging from $69.48 to $70.37 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 23:52 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 6,830 | $10.85 | $74,105.50 |
DisclosureSEC source: 0001628280-25-000403 · wk-form4_1735948354.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 240,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 23:52 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 18,750 | $69.84 | $1,309,500.00 |
DisclosureSEC source: 0001628280-25-000403 · wk-form4_1735948354.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 384,960 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 18,750 shares sold at prices ranging from $69.45 to $70.37 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 23:52 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 18,750 | $22.76 | $426,750.00 |
DisclosureSEC source: 0001628280-25-000403 · wk-form4_1735948354.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 403,710 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| December 19, 2024 Filed Dec 20, 2024 21:25 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 6,830 | $0.00 Strike: $10.85 | $0.00 |
DisclosureSEC source: 0001628280-24-052229 · wk-form4_1734729921.xml · derivative · entry 9 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 232,290 Underlying: Common Stock · 6,830 shares Expires 2026-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| December 19, 2024 Filed Dec 20, 2024 21:25 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 18,750 | $0.00 Strike: $22.76 | $0.00 |
DisclosureSEC source: 0001628280-24-052229 · wk-form4_1734729921.xml · derivative · entry 8 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 18,750 shares Expires 2025-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| December 19, 2024 Filed Dec 20, 2024 21:25 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 1,590 | $70.61 | $112,269.90 |
DisclosureSEC source: 0001628280-24-052229 · wk-form4_1734729921.xml · nonDerivative · entry 6 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 233,924 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · price: This is the weighted average sales price representing 1,590 shares sold at prices ranging from $70.36 to $70.91 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| December 19, 2024 Filed Dec 20, 2024 21:25 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 5,240 | $69.71 | $365,280.40 |
DisclosureSEC source: 0001628280-24-052229 · wk-form4_1734729921.xml · nonDerivative · entry 5 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 235,514 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 5,240 shares sold at prices ranging from $69.28 to $70.27 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| December 19, 2024 Filed Dec 20, 2024 21:25 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 6,830 | $10.85 | $74,105.50 |
DisclosureSEC source: 0001628280-24-052229 · wk-form4_1734729921.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 240,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| December 19, 2024 Filed Dec 20, 2024 21:25 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 5,588 | $70.52 | $394,065.76 |
DisclosureSEC source: 0001628280-24-052229 · wk-form4_1734729921.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 384,960 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 5,588 shares sold at prices ranging from $70.23 to $70.91 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| December 19, 2024 Filed Dec 20, 2024 21:25 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 13,162 | $69.65 | $916,733.30 |
DisclosureSEC source: 0001628280-24-052229 · wk-form4_1734729921.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 390,548 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 13,162 shares sold at prices ranging from $69.22 to $70.22 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| December 19, 2024 Filed Dec 20, 2024 21:25 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 18,750 | $22.76 | $426,750.00 |
DisclosureSEC source: 0001628280-24-052229 · wk-form4_1734729921.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 403,710 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| December 12, 2024 Filed Dec 13, 2024 21:16 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 6,830 | $0.00 Strike: $10.85 | $0.00 |
DisclosureSEC source: 0001628280-24-051195 · wk-form4_1734124566.xml · derivative · entry 11 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 239,120 Underlying: Common Stock · 6,830 shares Expires 2026-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F9 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| December 12, 2024 Filed Dec 13, 2024 21:16 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 18,750 | $0.00 Strike: $22.76 | $0.00 |
DisclosureSEC source: 0001628280-24-051195 · wk-form4_1734124566.xml · derivative · entry 10 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 131,250 Underlying: Common Stock · 18,750 shares Expires 2025-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F9 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| December 12, 2024 Filed Dec 13, 2024 21:16 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 181 | $74.22 | $13,433.82 |
DisclosureSEC source: 0001628280-24-051195 · wk-form4_1734124566.xml · nonDerivative · entry 8 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 233,924 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F8 · price: This is the weighted average sales price representing 181 shares sold at prices ranging from $74.20 to $74.30 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| December 12, 2024 Filed Dec 13, 2024 21:16 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 2,562 | $73.55 | $188,435.10 |
DisclosureSEC source: 0001628280-24-051195 · wk-form4_1734124566.xml · nonDerivative · entry 7 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 234,105 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F7 · price: This is the weighted average sales price representing 2,562 shares sold at prices ranging from $73.16 to $74.11 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| December 12, 2024 Filed Dec 13, 2024 21:16 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 4,087 | $72.57 | $296,593.59 |
DisclosureSEC source: 0001628280-24-051195 · wk-form4_1734124566.xml · nonDerivative · entry 6 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 236,667 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6 · price: This is the weighted average sales price representing 4,087 shares sold at prices ranging from $72.05 to $73.01 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| December 12, 2024 Filed Dec 13, 2024 21:16 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 6,830 | $10.85 | $74,105.50 |
DisclosureSEC source: 0001628280-24-051195 · wk-form4_1734124566.xml · nonDerivative · entry 5 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 240,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| December 12, 2024 Filed Dec 13, 2024 21:16 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 399 | $74.23 | $29,617.77 |
DisclosureSEC source: 0001628280-24-051195 · wk-form4_1734124566.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 384,960 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · price: This is the weighted average sales price representing 399 shares sold at prices ranging from $74.18 to $74.36 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| December 12, 2024 Filed Dec 13, 2024 21:16 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 6,847 | $73.56 | $503,665.32 |
DisclosureSEC source: 0001628280-24-051195 · wk-form4_1734124566.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 385,359 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 6,847 shares sold at prices ranging from $73.16 to $74.14 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| December 12, 2024 Filed Dec 13, 2024 21:16 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 11,504 | $72.58 | $834,960.32 |
DisclosureSEC source: 0001628280-24-051195 · wk-form4_1734124566.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 392,206 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 11,504 shares sold at prices ranging from $72.05 to $73.05 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| December 12, 2024 Filed Dec 13, 2024 21:16 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 18,750 | $22.76 | $426,750.00 |
DisclosureSEC source: 0001628280-24-051195 · wk-form4_1734124566.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 403,710 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes 835 shares acquired through the Company's 2018 Employee Stock Purchase Plan. Read SEC document |
| May 14, 2024 Filed May 15, 2024 20:34 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 22,198 | $25.52 | $566,492.96 |
DisclosureSEC source: 0001628280-24-023600 · wk-form4_1715805282.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 384,125 F3 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of RSUs and to cover related broker fees. F4 · price: This is the weighted average sales price representing 22,198 shares sold at prices ranging from $25.41 to $25.67 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| May 13, 2024 Filed May 15, 2024 20:34 UTC | INSMED Inc INSM · Entity 3174 | GrantStock Option (right to buy) · Derivative | 209,320 | $0.00 Strike: $25.83 | $0.00 |
DisclosureSEC source: 0001628280-24-023600 · wk-form4_1715805282.xml · derivative · entry 5 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,320 Underlying: Common Stock · 209,320 shares Expires 2034-05-13 F5 · derivative.exercise_date: These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the Initial Vesting Date and an additional 12.5% vest every six months thereafter through the fourth anniversary of the Initial Vesting Date. Read SEC document |
| May 13, 2024 Filed May 15, 2024 20:34 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 42,707 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-023600 · wk-form4_1715805282.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 406,323 F1 · shares: Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan, as amended. The RSUs vest as follows: 25% percent on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 25% on each anniversary of the Initial Vesting Date until fully vested. F2 · price: Each RSU was granted on May 13, 2024 for no consideration. Read SEC document |
| February 28, 2024 Filed Feb 29, 2024 21:08 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $12.58 | $0.00 |
DisclosureSEC source: 0001628280-24-007970 · wk-form4_1709240860.xml · derivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By ARTICLE 4 UNDER WILLIAM LEWIS FAMILY LEGACY TRUST U/A 11/1/2020 Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2024-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| February 28, 2024 Filed Feb 29, 2024 21:08 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 50,000 | $12.58 | $629,000.00 |
DisclosureSEC source: 0001628280-24-007970 · wk-form4_1709240860.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By ARTICLE 4 UNDER WILLIAM LEWIS FAMILY LEGACY TRUST U/A11/1/2020 Disclosed balance after: 50,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 09, 2024 Filed Jan 10, 2024 21:15 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 9,887 | $28.72 | $283,954.64 |
DisclosureSEC source: 0001628280-24-001036 · wk-form4_1704921303.xml · nonDerivative · entry 5 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 363,651 F4 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of Restricted Stock Units and to cover related broker fees. F5 · price: This is the weighted average sales price representing 9,887 shares sold at prices ranging from $28.62 to $28.84 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 08, 2024 Filed Jan 10, 2024 21:15 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 45,120 | $20.49 Strike: $20.49 | $924,508.80 |
DisclosureSEC source: 0001628280-24-001036 · wk-form4_1704921303.xml · derivative · entry 8 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,120 shares Expires 2024-01-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6 · derivative.exercise_date: Stock options granted under the Company's 2013 Incentive Plan. The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each sixth month anniversary date thereafter through the fourth anniversary date of the date of grant. All options are currently exercisable and were scheduled to expire on January 10, 2024. Read SEC document |
| January 08, 2024 Filed Jan 10, 2024 21:15 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 20,169 | $29.88 | $602,649.72 |
DisclosureSEC source: 0001628280-24-001036 · wk-form4_1704921303.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 373,538 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 20,169 shares sold at prices ranging from $29.88 to $29.93 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 08, 2024 Filed Jan 10, 2024 21:15 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 20,169 | $20.49 | $413,262.81 |
DisclosureSEC source: 0001628280-24-001036 · wk-form4_1704921303.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 393,707 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.